Acorda Therapeutics
ACOR
ACOR was delisted on the 11th of April, 2024.
15 hedge funds and large institutions have $2.35M invested in Acorda Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
2% more capital invested
Capital invested by funds: $2.3M → $2.35M (+$48.3K)
6% less funds holding
Funds holding: 16 → 15 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$13.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.86K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$839 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$567 |
| 5 |
JP Morgan Chase
New York
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$25.5K |
| 2 |
Renaissance Technologies
New York
|
-$3.4K |
| 3 |
BlackRock
New York
|
-$1.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$615 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$11 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DKCM
1
Davidson Kempner Capital Management
New York
| $801K | – | – | – |
|
|
2
Renaissance Technologies
New York
| $691K | -$3.4K | -300 | -0.7% |
|
3
Acadian Asset Management
Boston,
Massachusetts
| $489K | – | – | – |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $163K | +$839 | +74 | +0.7% |
|
|
5
BlackRock
New York
| $100K | -$1.7K | -150 | -2% |
|
6
Wells Fargo
San Francisco,
California
| $56.5K | +$11 | +1 | +0% |
|
|
7
Morgan Stanley
New York
| $35.5K | +$13.3K | +1,176 | +100% |
|
|
8
UBS Group
Zurich,
Switzerland
| $4.5K | +$1.86K | +164 | +122% |
|
9
Russell Investments Group
London,
United Kingdom
| $4.36K | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| $754 | +$567 | +50 | New |
|
11
First Manhattan
New York
| $45 | – | – | – |
|
|
12
JP Morgan Chase
New York
| $44 | +$11 | +1 | +50% |
|
|
13
Osaic Holdings
Scottsdale,
Arizona
| $15 | -$11 | -1 | -50% |
|
14
Qube Research & Technologies (QRT)
London,
United Kingdom
| $15 | – | – | – |
|
|
15
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$25.5K | -1,700 | Closed |
|
|
TRCT
16
Tower Research Capital (TRC)
New York
| – | -$615 | -41 | Closed |
|
ACOR Hedge Fund Activity: Q4 2023 in Review
15 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q4 2023, worth a combined $2.35M — up 2.1% from $2.3M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ACOR and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Morgan Stanley, adding an estimated $13.3K. The largest seller was Deutsche Bank, exiting entirely with an estimated $25.5K sold.
- 15 institutional investors held Acorda Therapeutics (ACOR) as of Q4 2023, down from 16 in Q3 2023.
- Funds reported $2.35M of Acorda Therapeutics stock for Q4 2023, up 2.1% quarter-over-quarter.
- 1 fund opened new Acorda Therapeutics positions in Q4 2023 and 2 closed out, a net change of -1 holder.
- The largest Acorda Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $13.3K added.
- The largest Acorda Therapeutics seller in Q4 2023 was Deutsche Bank, an estimated $25.5K sold.
Based on aggregated 13F filings for Q4 2023.